Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM120 in Healthy Adult Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03392116

Enrollment

Registered

2018-01-05

Start date

2018-01-29

Completion date

2019-03-11

Last updated

2019-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cachexia

Brief summary

The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects

Interventions

BIOLOGICALNGM120

Subcutaneous Injection

OTHERPlacebo

Subcutaneous Injection

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Normal ECG findings

Exclusion criteria

* Significant history or clinical manifestation of any allergic, dermatological, hepatic, renal, hematological, pulmonary, metabolic, cardiovascular, gastrointestinal, neurological, or psychiatric disorder

Design outcomes

Primary

Measure	Time frame	Description
Part A Arm-Single Dose: Treatment Emergent Adverse events	28 days	Percentage of total subjects with Treatment Emergent Adverse event
Part B Arm-Multiple Dose: Treatment Emergent Adverse events	84 days	Percentage of total subjects with Treatment Emergent Adverse event

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026